Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT02289690. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination With Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study seeks to assess the efficacy of veliparib (ABT-888) in combination with carboplatin and etoposide in participants with extensive disease small cell lung cancer (ED SCLC).
Study identification
- NCT ID
- NCT02289690
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 221 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 13, 2014 (Actual)
- Primary completion
- Apr 17, 2019 (Actual)
- Completion
- Apr 17, 2019 (Actual)
- Last update posted
- May 14, 2020
2014 – 2019
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic - Scottsdale /ID# 129127 | Scottsdale | Arizona | 85259 | — |
| Univ of Colorado Cancer Center /ID# 129220 | Aurora | Colorado | 80045 | — |
| Emory University Hospital /ID# 141682 | Atlanta | Georgia | 30322 | — |
| Georgia Regents University /ID# 148567 | Augusta | Georgia | 30912 | — |
| Northwestern University Feinberg School of Medicine /ID# 137088 | Chicago | Illinois | 60611-2927 | — |
| Herbert Herman Cancer Center /ID# 167020 | Lansing | Michigan | 48912 | — |
| Gabrail Cancer Center Research /ID# 129216 | Canton | Ohio | 44718 | — |
| Allegheny General Hospital /ID# 147328 | Pittsburgh | Pennsylvania | 15212 | — |
| University of Texas MD Anderson Cancer Center /ID# 129213 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02289690, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 14, 2020 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02289690 live on ClinicalTrials.gov.